Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.65 |
| ▸ | PPARG | P37231 | 6/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | CTSS | P25774 | 6/20 | 0.56 |
| ▸ | CTSK | P43235 | 5/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309909 | 1.00 | PPARA (0.65) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL181848 | 1.00 | PPARA (0.65) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3722240 | 0.96 | PPARA (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL22009950 | 0.96 | PPARA (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL3722245 | 0.96 | PPARA (0.61) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL2290585 | 0.94 | ITGB3 (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL2290589 | 0.94 | ITGB3 (0.62) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL2287582 | 0.91 | ITGB3 (0.59) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL2287578 | 0.91 | ITGB3 (0.59) | PPARAPPARGACEITGB3ITGA2B | |
| SCHEMBL7481627 | 0.89 | PPARG (0.59) | PPARAPPARGACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| EP-4269400-B1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE SA (PL) | 2025-07-09 | — | — | EP | disclosed |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-5929067-A | N-ACYLATING AMINE DERIVATIVE OF CAPROLACTAM COMPOUND WITH A CARBOXYLIC ACID OR DERIVATIVES TO FORM AMIDE DERIVATIVE OF CAPROLACTAM COMPOUND | NOVARTIS AG (CH) | 1999-07-27 | — | — | US | disclosed |
| EP-0810991-B1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1999-04-14 | — | — | EP | disclosed |
| CN-1175944-A | 1 -aryl -2 -acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists | CIBA GEIGY AG (CH) | 1998-03-11 | — | — | CN | disclosed |
| EP-0810991-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | Novartis AG (CH) | 1997-12-10 | — | — | EP | disclosed |
| US-5578601-A | Nonpeptide bradykinin antagonists | STERLING WINTHROP INC. (US) | 1996-11-26 | — | — | US | disclosed |
| WO-1996026183-A1 | 1-ARYL-2-ACYLAMINO-ETHANE COMPOUNDS AND THEIR USE AS NEUROKININ ESPECIALLY NEUROKININ 1 ANTAGONISTS | NOVARTIS AG (CH) | 1996-08-29 | — | — | WO | disclosed |
| US-5510380-A | TREATING INFLAMMATORY CONDITIONS | STERLING WINTHROP, INC. (US) | 1996-04-23 | — | — | US | disclosed |
| US-5250517-A | Hypotensive and cardiotonic agents; cardiac insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0071926-B1 | NEW RIBOFURANURONIC ACID DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4479942-A | Tetrahydrofurnancarboxylic acid derivatives, processes for preparation thereof and pharmaceutical compositions thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | PPARA 3678/4885PPARG 2613/4885ACE 1597/4885 |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | PPARA 4557/4885PPARG 4544/4885ACE 1071/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | PPARA 3678/4885PPARG 2613/4885ACE 1597/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | PPARA 4651/4885PPARG 4735/4885ACE 1625/4885 |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | PPARA 3732/4885PPARG 3094/4885ACE 3909/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | PPARA 3678/4885PPARG 2613/4885ACE 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.